Response to COVID-19 vaccination imaged by PD-L1 PET scanning
Background During a phase 0 clinical trial of an investigational programmed cell death
ligand-1 (PD-L1) PET tracer in patients with non-small cell lung cancer (NSCLC), three …
ligand-1 (PD-L1) PET tracer in patients with non-small cell lung cancer (NSCLC), three …
Highlights of radioisotope, radiochemistry, and radiotracer development in Australia
ML Aulsebrook, L Hogan… - Australian journal of …, 2020 - CSIRO Publishing
Australia has a rich and long history in the nuclear science and technology sector. Nuclear
medicine involves the use of radioactive substances and molecular imaging equipment to …
medicine involves the use of radioactive substances and molecular imaging equipment to …
Mixed Liquid and Solid Phase Synthesis of Isopeptidic Desferrioxamine Analogues for Complexation of Zirconium
L Outzen, HD Nguyen, D Ludolfs… - European Journal of … - Wiley Online Library
89Zr has a number of advantageous properties for PET‐imaging, but optimal chelators for its
widespread clinical application still need to be found. Tetrahydroxamates derived from the …
widespread clinical application still need to be found. Tetrahydroxamates derived from the …
Nonmacrocyclic ligand development for inorganic radiopharmaceutical chemistry
LD Southcott - 2022 - open.library.ubc.ca
Advances in nuclear medicine include new chelating ligands that form highly stable and
kinetically inert complexes with relevant radiometal ions for use in diagnosis or therapy …
kinetically inert complexes with relevant radiometal ions for use in diagnosis or therapy …
[PDF][PDF] Bifunctional chelators containing dibromomaleimides for the preparation of radioimmunoconjugates for PET imaging
M Farleigh - 2022 - kclpure.kcl.ac.uk
Molecular imaging enables the visualisation of biochemical events occurring at the
molecular and cellular level. This contrasts with conventional methods for obtaining …
molecular and cellular level. This contrasts with conventional methods for obtaining …
Biologické testování cetuximabu značeného 89Zr
D Lucie - 2023 - dspace.cvut.cz
Tato práce se zabývá testováním cetuximabu značeného pomocí 89Zr, ke značení byl použit
chelátor desferrioxamin B squaramid (DFOSq). K přípravě konjugátu cetuximabu s DFOSq …
chelátor desferrioxamin B squaramid (DFOSq). K přípravě konjugátu cetuximabu s DFOSq …
[PDF][PDF] Development of modified nucleosides for targeting the DNA repair enzyme SNM1A
M Berney - 2022 - tara.tcd.ie
Development of modified nucleosides for targeting the DNA repair enzyme SNM1A Page 1
Development of modified nucleosides for targeting the DNA repair enzyme SNM1A A thesis …
Development of modified nucleosides for targeting the DNA repair enzyme SNM1A A thesis …
[PDF][PDF] 2.1. Author Contribution and Relation to the Research Objectives
E Khozeimeh Sarbisheh, S AK… - … of Chelators for …, 2022 - harvest.usask.ca
Herein we report a new high-denticity chelator based on the iron siderophore
desferrioxamine (DFO). Our new chelator–DFO2–is acyclic and was designed and …
desferrioxamine (DFO). Our new chelator–DFO2–is acyclic and was designed and …
[PDF][PDF] Рекомбинантные клетки как инструмент для оценки специфической активности меченных радионуклидами антител против эндоглина (CD105)
М БИОТЕХНОЛОГИЯ - Биотехнология, 2022 - researchgate.net
Одна из важнейших характеристик меченных радионуклидами антител и их
производных‒размер иммунореактивной фракции. Для измерения этого параметра …
производных‒размер иммунореактивной фракции. Для измерения этого параметра …
[PDF][PDF] DEVELOPMENT OF RADIOPHARMACEUTICALS FOR PET IMAGING OF INFLAMMATION
O Moisio - utupub.fi
Positron emission tomography (PET) is a non-invasive technology widely used in oncology,
cardiology, neurology and inflammation imaging. PET can detect the expression of …
cardiology, neurology and inflammation imaging. PET can detect the expression of …